The estimated Net Worth of Michael F Mac Lean is at least $3.3 Million dollars as of 17 June 2024. Mr Lean owns over 11,228 units of Avidity Biosciences stock worth over $2,345,847 and over the last 18 years he sold RNA stock worth over $455,722. In addition, he makes $501,336 as Chief Financial Officer at Avidity Biosciences.
Mr has made over 6 trades of the Avidity Biosciences stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 11,228 units of RNA stock worth $439,352 on 17 June 2024.
The largest trade he's ever made was exercising 104,245 units of Avidity Biosciences stock on 12 June 2024 worth over $919,441. On average, Mr trades about 6,660 units every 174 days since 2007. As of 17 June 2024 he still owns at least 57,865 units of Avidity Biosciences stock.
You can see the complete history of Mr Lean stock trades at the bottom of the page.
Michael F. MacLean is the Chief Financial Officer at Avidity Biosciences.
As the Chief Financial Officer of Avidity Biosciences, the total compensation of Mr MacLean at Avidity Biosciences is $501,336. There are 1 executives at Avidity Biosciences getting paid more, with Sarah Boyce having the highest compensation of $823,093.
Mr MacLean is 55, he's been the Chief Financial Officer of Avidity Biosciences since . There are 4 older and 2 younger executives at Avidity Biosciences. The oldest executive at Avidity Biosciences, Inc. is Dr. Frank McCormick Ph.D., 71, who is the Scientific Founder & Member of Scientific Advisory Board.
Michael's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Avidity Biosciences have traded over $8,545,325 worth of Avidity Biosciences stock and bought 2,050,000 units worth $36,900,000 . The most active insiders traders include Investments, Lpwong Roderic..., Lilly & Co Eli, and Asset Management, Lp Chen B.... On average, Avidity Biosciences executives and independent directors trade stock every 34 days with the average trade being worth of $3,142,336. The most recent stock trade was executed by Arthur A Levin on 19 August 2024, trading 5,000 units of RNA stock currently worth $6,200.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences executives and other stock owners filed with the SEC include: